DHRNYSEIndustrial Instruments For Measurement, Display, and ControlUS GAAP · USD

Danaher Corporation

Danaher is a U.S.-based science and technology company organized around biotechnology, life sciences, and diagnostics. It develops instruments, consumables, and services used by healthcare, research, and industrial customers, with a business model built around recurring sales, direct selling, and the Danaher Business System operating discipline.

Ask about the company
Revenue24.6bn USD
+2.9 %y/y
Operating profit (EBIT)4,690m USD
−3.6 %y/y
EBIT margin19.1%
−1.3 ppy/y
Net income3,614m USD
−7.3 %y/y
Free cash flow5,260m USD
−0.7 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

0102030bn USD2020: 22.3 bn USD2020: EBIT 4.2 bn USD20202021: 29.5 bn USD2021: EBIT 7.5 bn USD20212022: 26.6 bn USD2022: EBIT 7.5 bn USD20222023: 23.9 bn USD2023: EBIT 5.2 bn USD20232024: 23.9 bn USD2024: EBIT 4.9 bn USD20242025: 24.6 bn USD2025: EBIT 4.7 bn USD202524.64.7
RevenueOperating profit (EBIT)
Ask Clarifo about Danaher Corporation

Business

Share of revenue
Biotechnology35 %

Tools and consumables used in bioprocessing and biologics manufacturing workflows.

Life Sciences30 %

Instruments, reagents, and workflow products for research and analytical applications.

Diagnostics30 %

Clinical diagnostic systems, tests, and related service offerings for healthcare settings.

Services and Recurring Consumables5 %

Installed-base consumables, maintenance, and support tied to recurring customer usage.

Products

Reported · share of revenue
81.9%18.1%FY2025100 %
  • Revenuefrom Contractwith Customer Measurement Recurring81.9 %
  • Revenuefrom Contractwith Customer Measurement Nonrecurring18.1 %

Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.

Customers

Danaher sells primarily to healthcare providers, clinical laboratories, biopharma manufacturers, and research institutions that need reliable instruments and consumables. Its diagnostics customers value accuracy, speed, productivity, and service support, while life sciences and biotechnology customers buy products that improve workflow efficiency and support regulated scientific processes. The company also serves a geographically diverse customer base through direct sales and independent distributors.

Clinical diagnostics customers

Hospitals, labs, and healthcare systems buy diagnostic platforms and tests to improve accuracy, speed, and productivity.

Biopharma manufacturers

Drug and biologics producers buy biotechnology tools and consumables for recurring manufacturing workflows.

Research and academic labs

Universities, institutes, and applied research labs buy life sciences instruments and reagents for analysis and discovery.

Industrial and applied science customers

Selected customers use measurement and control-related products in specialized scientific and industrial workflows.

Strategy

Danaher’s strategy centers on applying the Danaher Business System to improve execution, margins, and customer responsiveness. Management is also prioritizing portfolio expansion in attractive science and technology markets, acquisitions and strategic partnerships, and investment in talent and globalized manufacturing and R&D. The company is positioning itself for growth in high-growth geographies and digitally enabled, higher-margin products.

Strengthen competitive advantage through DBSShort term

Operational discipline is central to Danaher's margin structure, quality systems, and execution consistency.

Reallocate capital toward attractive science and technology marketsMedium term

Portfolio mix drives long-term growth and helps shift exposure toward higher-value end markets.

Globalize manufacturing and customer resourcesMedium term

A broader global footprint improves responsiveness to customers and supports growth in high-growth regions.

Attract and retain exceptional talentLong term

Technical product development and regulated markets depend on specialized scientific and commercial talent.

Geography

Danaher is globally diversified, with about 59% of 2025 sales coming from outside the United States. The company says its R&D, manufacturing, sales, distribution, service, and administrative footprint spans roughly 50 countries, and it highlights significant presence in China, Denmark, Germany, Singapore, Sweden, Switzerland, and the United Kingdom. This global footprint helps diversify demand but also increases exposure to currency, regulation, trade, and local operating risks.

Risks

Danaher faces competition in highly regulated, technology-driven markets where product quality, service, and innovation can quickly shift share. Its global footprint creates exposure to foreign exchange, geopolitical, tax, and local compliance risks, while acquisitions add integration and goodwill/intangible impairment risk. Because many products are sold on a recurring basis into healthcare and life-science workflows, demand can also be affected by customer spending cycles, regulation, and pricing pressure.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Competition and pricing pressure1International regulatory and geopolitical exposure2Goodwill and intangible asset impairment3Intellectual property and counterfeiting4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Competition and pricing pressureImpact: HighLikelihood: Medium

    The company operates in crowded science and diagnostics markets with specialized and well-funded rivals.

    ExposureBiotechnologyLife sciencesDiagnostics
  2. International regulatory and geopolitical exposureImpact: HighLikelihood: Medium

    A majority of sales are outside the U.S., and operations span many jurisdictions with different rules and tax regimes.

    ExposureChinaEuropeOther non-U.S. markets
  3. Goodwill and intangible asset impairmentImpact: MediumLikelihood: High

    Acquisitions create reporting units and intangible assets whose fair values depend on future cash flow assumptions.

    Exposure: Recent acquisitions and reorganized reporting units

  4. Intellectual property and counterfeitingImpact: MediumLikelihood: Low

    The company relies on patents, trademarks, and proprietary technology that may be harder to enforce in some countries.

    Exposure: Non-U.S. jurisdictions with weaker IP protection

Ask Clarifo about Danaher Corporation

Accounting

Judgemental items
Goodwill impairment testing

Reporting unit fair values depend on forecasted EBITDA, discount rates, and market multiples.

Impact: Can create material non-cash impairment charges if assumptions weaken

Acquired intangible asset valuation

Purchase accounting assigns value to developed technology and other intangibles based on estimates.

Impact: Affects amortization expense and future impairment risk

Core sales non-GAAP adjustment

Management excludes acquisitions and currency translation to show underlying growth trends.

Impact: Important for comparing organic demand versus M&A-driven growth

Foreign currency translation

A large share of revenue is generated outside the U.S., creating translation effects.

Impact: Can materially change reported sales growth and margins

Similar listed companies

Publicly listed companies with a comparable business focus.

Thermo Fisher Scientific Inc

TMO · Measuring & Controlling Devices, NEC

Natera, Inc.

NTRA · Services-Medical Laboratories

Qiagen N.V

QGEN · Biological Products, (No Diagnostic Substances)

Avantor, Inc.

AVTR · Laboratory Analytical Instruments

DLH Holdings Corp.

DLHC · Services-Help Supply Services

Harvard Bioscience, Inc

HBIO · Laboratory Analytical Instruments

Last updated: 24/09/2026